Market For Anti-Obesity Drugs In US Has Been Largely “Flat,” Despite Expectations.

reports that the market for anti-obesity drugs has generally been “flat” in the US. According to STAT, “analysts were predicting that anti-obesity drugs could ring up as much as $3 billion in sales by 2020” as “early as five years ago.” Ultimately, “physicians proved reticent to prescribe the new drugs as they hit the market, in part because of a cultural reluctance to see obesity as a disease requiring medication.” In addition, many patients “see only modest benefits” from such drugs and “cost is an issue, as many insurers still aren’t paying for weight loss [drugs].” https://www.statnews.com/2016/05/17/obesity-pill-market/